Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BioInvent International AB
Prescient Therapeutics, Ltd.
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Institute of Hematology & Blood Diseases Hospital, China
Columbia University
Mayo Clinic
Mayo Clinic
SciTech Development, Inc.
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Beijing GoBroad Hospital
Memorial Sloan Kettering Cancer Center
Beijing GoBroad Hospital
City of Hope Medical Center
Yale University
Ohio State University Comprehensive Cancer Center
BeiGene
Northwestern University
Columbia University
National Institutes of Health Clinical Center (CC)
miRagen Therapeutics, Inc.
Alexion Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
miRagen Therapeutics, Inc.
University of California, San Francisco
Shandong Provincial Hospital
Acrotech Biopharma Inc.
Mayo Clinic
National Cancer Institute (NCI)
Angimmune LLC
Janssen Research & Development, LLC
Rhizen Pharmaceuticals SA
National Cancer Institute (NCI)
Samsung Medical Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Pfizer
Eisai Inc.